Conclusion:
This study revealed worse outcomes in pregnant patients infected with COVID-19 and with associated transaminitis. Due to limited data and overall information on COVID-19, it is difficult to determine if transaminitis serves as a predictor of worse outcomes, or if it is solely a marker of worsening disease. As more data becomes available on pregnant patients with COVID-19, it will be important to assess the effect of transaminitis on maternal and neonatal outcomes and if it is consistently predictive of poor outcomes. In the future, it will be crucial to determine if transaminitis can help determine clinical guidelines, such as timing of delivery.
Disclosure of Interest: All authors report no conflicts of interest.
Contribution to authorship : JAY, SJW, and GR conceived and designed the study. GR and SK supervised the study. SF was responsible for literature review. JAY, SJW and SF acquired and analyzed the data. JAY did the statistical analysis. JAY, SJW, SF, SK, and GR interpreted the data, were involved in preparing the manuscript and contributed to the critical revision of the manuscript. The corresponding author attests that all listed authors meeting authorship criteria. All authors accept responsibility for the paper as published.
Details of ethic approval : This study was approved by New York Medical College and Westchester Medical College Institutional Review Board (IRB), protocol #14296 on September 8th, 2020. Written consent was not required for this study because it was a case series and retrospective in nature. Therefore, the research involves no risk to the subjects the waiver or alteration will not adversely affect the rights and welfare of the subjects; the research could not practicably be carried out without the waiver or alteration (i.e., it is impracticable to get consent of the subjects).
Funding: No sources of funding or financial support provided for this research.
Acknowledgements: None.